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1015-9584/Copyright ª 2014, Asian SuSummary Objective: We have performed laparoscopic adrenalectomy including retroperito-
neoscopic adrenalectomy via a single large port (RASLP) and conventional laparoscopic adre-
nalectomy (CLA) for adrenal tumors since 1992, and report our experience to date.
Methods: The study population consisted of 134 patients who underwent laparoscopic adrenal-
ectomy from 1992 to 2012. Fifty-eight patients (18 aldosterone-producing adenomas, 13 ade-
nomas with Cushing’s syndrome, 1 adenoma with preclinical Cushing’s syndrome, and 26
nonfunctioning tumors) were treated using RASLP, and 76 patients (33 aldosterone-producing
adenomas, 17 adenomas with Cushing’s syndrome, 6 adenomas with preclinical Cushing’s syn-
drome, 17 pheochromocytomas, and 3 nonfunctioning tumors) were treated using CLA. Com-
plications were graded according to the modified Clavien system.
Results: The majority of RASLPs were performed during the 1990s, whereas all patients under-
went CLA after 2000. The mean operation times (166 vs. 205 minutes, p < 0.01) and intrao-
perative estimated blood loss (85 vs. 247 mL, p < 0.01) were significantly lower in the CLA
group. Conversion to open surgery was required in three patients (5%) in the RASLP group
and five patients (7%) in the CLA group (p Z 0.73). Postoperative complications were gradeng authors declare no conflicts of interest.
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rgical Association. Published by Elsevier Taiwan LLC. All rights reserved.
80 D. Hirano et al.1 in three patients and grades 4 and 5 in one patient each in the RASLP group, whereas grade 2
in one patient was observed in the CLA group (p Z 0.085).
Conclusion: Although this study included biases such as different eras and indications, CLA re-
sulted in decreased operative times, blood loss, and postoperative complications compared
with RASLP. CLA has so far become our preferred procedure for patients with adrenal tumor
in our experience.
Copyright ª 2014, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
In 1985, Buess et al1 performed endoscopic surgery of the
rectum using a rectoscope 4 cm in diameter and with a
large working lumen. We first performed retroperitoneo-
scopic adrenalectomy via a single large port (RASLP) using
this wide-lumen rectoscope to treat a small adrenal tumor
without carbon dioxide insufflation in 1992.2 We subse-
quently performed RASLP routinely, reporting the tech-
niques involved and outcomes in 2005.3 Our unique
procedure introduced a template for the development of
laparoendoscopic single-site surgery (LESS),4 which has
seen increasing uptake recently with advancements in
surgical instruments, greater consideration of cosmetics,
and the trend towards minimal invasiveness. Indeed, there
has been a paradigm shift in the field of minimally invasive
surgery, as laparoscopy progresses towards scar-free tech-
niques. Although different techniques and devices have
been reported in the published data on surgery with various
terminologies and acronyms applied, natural orifice trans-
lumenal endoscopic surgery5 and LESS6 are emerging in an
effort to duplicate standard laparoscopic procedures
through a virtually scar-free approach.
By contrast, since the introduction of the laparoscopic
approach to adrenalectomy in 1992 by Gagner et al,7 this
minimally invasive technique has gained worldwide accep-
tance and has become the gold standard for the removal of
most small, benign lesions of the adrenal gland as con-
ventional laparoscopic adrenalectomy (CLA) including
lateral transperitoneal and retroperitoneal approaches. We
have also performed CLA routinely for adrenal tumors
including even relatively large tumors and pheochromocy-
toma since the year 2000. The purpose of this study was to
evaluate our single-center experience with RASLP and CLA
performed for a variety of adrenal tumors.
2. Materials and methods
We reviewed the records of all patients undergoing lapa-
roscopic adrenalectomy at our institution (Nihon University
Itabashi Hospital, Tokyo, Japan) from May 1992 to
December 2012. Data were extracted from institutional
review board-approved databases. Data extracted included
patient age, sex, body mass index (BMI), operative history,
tumor size, side effects of disease, and characteristics on
imaging and clinical diagnosis. In addition, information
relating to the perioperative course such as operative time,
estimated blood loss, conversion to open surgery,perioperative mortality, complications, postoperative hor-
monal prognosis in functioning tumors, and tumor recur-
rence was extracted from the operative notes, anesthesia
records, and inpatient and outpatient charts.
RASLP was indicated for unilateral and small benign
adrenal tumors (<4.5 cm in diameter) excluding pheo-
chromocytoma, whereas CLA was indicated for all benign
adrenal tumors with the exception of those with malignant
potential. Surgical indication of nonfunctioning adrenal
tumors after 2003 was according to the consensus confer-
ence on the topic at the National Institute of Health in
2002.8
The surgical technique of RASLP has been previously
described in detail.3 Briefly, patients were placed in the
lateral decubitus position with slight flexion, and a 4.5-cm
skin incision was made below the 12th rib in the mid axil-
lary line. The retroperitoneal space was dissected using
index fingers and a balloon dilator. A rectoscope tube (4 cm
in diameter) was inserted, and the adrenal glands were
endoscopically removed via the single large port without
carbon dioxide insufflation. Figure 1 shows an operating
scene including a tube of rectoscope inserting into the
retroperitoneal space and a retroperitoneoscopic finding,
and postoperative scar.
CLA including transperitoneal lateral and retroperito-
neal lateral approaches were performed using standard
techniques with small modifications routinely using multi-
ple ports and carbon dioxide insufflation.9 In the trans-
peritoneal approach, the primary port site was located at
the lateral margin of the ipsilateral rectus muscle at the
level of the umbilicusor several fingerbreadths above the
umbilicus. Secondary ports were placed in the anterior
axillary line/ipsilateral rectus near the costal margin. An
auxiliary port was necessary for retraction of the liver on
the right side (Figure 2). The abdominal cavity was insuf-
flated to 8e12 mmHg using carbon dioxide. On the left side,
the renal hilum was directly approached to expose the
renal vein. The adrenal vein was identified on its cranial
surface and ligated. On the right side, the inferior vena
cava was identified and traced up to the gland that was
dissected primarily prior to ligating the short adrenal vein
as it enters the vena cava. All specimens were retrieved
within an endoscopic pouch through the primary port. In
the retroperitoneal approach, an initial port was made near
the tip of the 12th rib under the 11th rib, and the retro-
peritoneal space was extended with balloon distension.
After carbon dioxide insufflation of the retroperitoneum,
the other trocars were placed at the angle of the paraspinal
muscle and the origin of the 12th rib, and approximately
Figure 1 (A) Insertion of rectoscope tube into the retroperitoneal space; (B) retroperitoneoscopic finding; and (C) postoperative
scar from retroperitoneoscopic adrenalectomy via a single large port. R Z rectoscope tube; RtAT Z right adrenal tumor.
Laparoscopic adrenalectomy for adrenal tumors 81two fingerbreadths above the iliac crest near the anterior
superior iliac spine. Then the procedures were carried out
in a similar manner to previous reports.9 Our series was
mostly confined to expert operators in the CLA procedure
but was unconfined in the RASLP. Postoperative complica-
tions were graded according to the modified Clavien system
published in 2004.10
Demographic, clinical, and perioperative outcomes
including complications were compared for the two groups
using the Fisher exact test and the ManneWhitney U test.
StatView software (Abacus Concepts, Inc., Berkeley, CA,Figure 2 Placement of trocars for conventional trans-
peritoneal laparoscopic right adrenalectomy.USA) was used for all statistical analyses. All calculated p
values were two sided, and those <0.05 were considered
statistically significant.
3. Results
In the past 21 years, 134 laparoscopic adrenalectomies have
been performed on 134 patients with adrenal tumor. Of
these patients, 58 underwent RASLP and 76 received CLA
(67 transperitoneal lateral and 9 retroperitoneal lateral
approaches). The majority of RASLP treatments were per-
formed during the 1990s, whereas all patients underwent
CLA after 2000 (Figure 3). Table 1 details the patient and
disease characteristics. The distributions of age, sex, BMI,
tumor location, and tumor size were similar between the
two groups. In preoperative clinical diagnosis, the RASLP
group included a large number of nonfunctioning tumors
(45%) because of the lack of consensus for management of
patients with nonfunctioning adrenal tumors when per-
forming the RASLP prior to 2002, whereas the CLA group
included 17 (22%) pheochromocytomas. The histological
evaluation demonstrated that all of the functioning and
preclinical Cushing’s syndrome tumors except for pheo-
chromocytoma, across both groups, were adrenocortical
adenomas. The nonfunctioning tumors comprised 20 cases
of adrenocortical adenoma, and one case each of nodular
hyperplasia, pseudocyst, hemorrhagic cyst, ganglioneur-
oma, myelolipoma, and a metastatic tumor from lung
cancer in the RASLP group, and one case each of broncho-
genic cyst, cystic lymphangioma, and myelolipoma in the
CLA group.
Figure 3 Number of RASLP and CLA in generation distinction.
The majority of RASLP treatments were performed during the
1990s, whereas all patients underwent CLA after 2000.
CLA Z conventional laparoscopic adrenalectomy;
RASLPZ retroperitoneoscopic adrenalectomy via a single large
port.
Table 2 Intraoperative outcomes.
RASLP CLA p
Operative
time (min),
mean  SD
205  57
(range 92e320)
166  60
(range 68e442)
<0.01
Intraoperative
estimated
blood loss (mL),
mean  SD
247  293
(range 10e1700)
85  198
(range 3e600)
<0.01
Conversion to
open surgery
3 (5%) 5 (7%) 0.73
CLA Z conventional laparoscopic adrenalectomy;
RASLPZ retroperitoneoscopic adrenalectomy via a single large
port; SD Z standard deviation.
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(mean 166 vs. 205 minutes, p < 0.01) and intraoperative
estimated blood loss (mean 85 vs. 247 mL, p < 0.01) in the
CLA group were significantly decreased compared to those
in the RASLP group, whereas the population of conversion
to open surgery was lower in the RASLP group; however, the
difference between the groups was not statistically signif-
icant (p Z 0.73). Of the patients converted to open sur-
gery, two patients in the RASLP group experienced bleeding
requiring blood transfusion and one patient with Cushing’s
syndrome had an unidentified tumor due to excessive
retroperitoneal fat. In the CLA group, conversion to an open
surgery was required in five patients owing to bleeding inTable 1 Patient characteristics.
RASLP CLA p
No. of patients 58 76
Age (y), m  SD 50  10 48  15 0.53
Sex 0.72
Male 20 29
Female 38 47
BMI, m  SD 23.9  3.5 23.6  3.6 0.64
Clinical diagnosis <0.01
APA 18 33
Cushing’s syndrome 13 17
Pre-Cushing’s syndrome 1 6
Pheochromocytoma 1 7
Nonfunctioning tumor 26 3
Tumor location 0.86
Right 30 37
Left 28 39
Tumor size (cm), m  SD 2.6  1.1 2.7  1.2 0.95
APA Z aldosterone-producing adenoma; CLA Z conventional
laparoscopic adrenalectomy; RASLP Z retroperitoneoscopic
adrenalectomy via a single large port; SDZ standard deviation.one, adhesion to periadrenal adipose tissue and the vena
cava in three, and no identification of tumor in the
remaining case. An intraoperative outcome analysis be-
tween transperitoneal and retroperitoneal approaches
found no significant difference between these CLA sub-
groups in the evaluated factors including operative time,
intraoperative estimated blood loss, and conversion to
open surgery.
Overall, intra- and postoperative complications (Table 3)
were observed in 14 patients (10%). Intraoperative com-
plications in the RASLP group included grade 2 (hemor-
rhage) in four patients (7%), and grade 3 (pneumothorax) in
three patients (5%) during dissection of the retroperitoneal
space using a balloon dilator and fingers, whereas only one
patient (1%) in the CLA group experienced grade 2 due to
bleeding (p Z 0.02). Postoperative complications in the
RASLP group included grade 1 (superficial wound infection)
in three patients (5%) with Cushing’s syndrome, grade 4
(pulmonary thrombosis) in one patient (2%) with primary
aldosteronism that was complicated by presurgery atrial
fibrillation, and grade 5 (death) in one patient (2%) with
preclinical Cushing’s syndrome who had postoperatively
fulminant hepatitis. In contrast, only one patient (1%) in
the CLA group experienced grade 2 (ileus) in the post-
operative complications. No statistically significant differ-
ence was found between the groups (p Z 0.08).Table 3 Intra- and postoperative complications according
to the modified Clavien system.
RASLP CLA p
Intraoperative complications, n (%) 0.02
Grade 2 4 (7) 1 (1)
Grade 3 3 (5)
Postoperative complications, n (%) 0.08
Grade 1 3 (5)
Grade 2 1 (1)
Grade 4 1 (2)
Grade 5 1 (2)
CLA Z conventional laparoscopic adrenalectomy;
RASLPZ retroperitoneoscopic adrenalectomy via a single large
port.
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recurrence, all patients with functioning adrenocortical
adenoma or pheochromocytoma showed normal function
with no tumor relapse at a median follow up of 40 months.4. Discussion
Adrenal surgery rates have been increasing in conjunction
with the increased prevalence of incidental adrenal masses
found on routine cross-sectional imaging.11 Simhan et al12
reported that the mean number of adrenal procedures
performed per hospital with time increased from a mean
number of 2.9 in 1996 to 5.5 in 2009 based on data in the
northeastern United States (New York, New Jersey, and
Pennsylvania), and a shift was noted from very low volume
hospital to very high volume hospital in the proportion of
patients who underwent adrenal surgery. In our institution,
the average number of endoscopic adrenalectomies per-
formed was 6.4 per year, and recently this figure has
increased.
Endoscopic adrenalectomies, including the trans-
peritoneal lateral and retroperitoneal lateral approaches,
are currently the standard procedures used for treating
adrenal tumors. However, both conventional laparoscopic
approaches require several ports and carbon dioxide
insufflation to obtain a working space. As we have previ-
ously described,3 RASLP does not require carbon dioxide
and provides direct exposure to the adrenal gland, and
permits the removal of large tumors without fraction as
long as they are smaller than the diameter of the large
port. However, RASLP has major disadvantages including
the relatively wide skin incision compared with that in
hand-assisted laparoscopic procedures, a smaller working
space, and interference of instruments in the dissection
compared with CLA. The most important technical factor
for conducting the RASLP operation is the act of placing the
rectoscope tube appropriately in the center of the dis-
secting area and pressing the periadrenal adipose tissues
and surrounding organs with the tube. Thus, this procedure
is not appropriate for obese patients or for the treatment of
pheochromocytoma. In addition, there were no contem-
porary devices used for LESS surgery when performing
RASLP, and these major disadvantages resulted in
decreasing the number of RASLPs performed in the
following years; we have also shifted from RASLP to CLA for
all adrenal tumors that were indicated for laparoscopic
surgery since 2004.
The operative time and intraoperative estimated blood
loss were markedly decreased in the CLA group compared
with the RASLP group. The larger operative field of the
conventional transperitoneal approach helps to better
orientate and visualize familiar landmarks known from
open surgery. During treatment of adrenal tumors using the
CLA techniques, developed contemporary devices such as
bipolar vessel sealing device (Ligasure, Valleylab, Boulder,
Colorado, USA) and ultrasonic coagulating shears were used
in the majority of cases. CLA offers several advantages. In
the CLA group, the duration of surgery and estimated blood
loss in the initial 20 cases were significantly increased
compared to those in the subsequent 56 cases. However,
the operative time and estimated blood loss in the initial 20cases were similar to those in the subsequent cases in the
RASLP group because of undefined expert operators, as
previously described.3
An extensive review undertaken by Brunt13 indicated
that 37 of 1083 patients (3.4%) underwent conversions to
open adrenalectomy during CLA, based on a meta-analysis.
Shen et al14 demonstrated that significant independent
predictive factors for conversion to open surgery were
tumor size of 5 cm, BMI of 24 kg/m2, and pheochromo-
cytoma based on multivariate analysis. In our study, the
rates of conversion to open surgery were high, especially in
the CLA group, although all such cases in the CLA group
were experienced in the earlier learning curve, and
comprised three pheochromocytomas and one case each of
aldosterone-producing adenoma and cystic lymphagioma.
Catecholamine-induced hypertension occurred during
dissection in patients with pheochromocytoma in whom the
transperitoneal lateral approach was converted to open
surgery, and their tumors were relatively enlarged
(5e7 cm) and were adherent to periadrenal adipose tissues.
Treatment of relatively enlarged pheochromocytoma
should therefore be avoided even when using conventional
transperitoneal laparoscopic procedures in the early
learning curve phase. The patient with histologically cystic
lymphangioma who underwent CLA using the retroperito-
neal lateral approach was converted to open surgery
because there was no identifiable tumor.
Early complications rates of 0e15% in laparoscopic
adrenalectomy have been reported.15 General complica-
tions associated with laparoscopic adrenalectomy include
wound hematomas and infection, and deep vein throm-
bosis. Patients with Cushing’s syndrome are more prone to
infectious and thrombotic complications. Specific compli-
cations include injury to surrounding organs such as the
liver, pancreas, spleen, inferior vena cava, renal vessel,
diaphragm, and pleura. In this study, there were signifi-
cantly fewer perioperative complications in the CLA group
than the RASLP group. Only one patient (1%) experienced
grade 2 complication (bleeding requiring blood transfusion)
in the CLA group, whereas 12 patients (21%) in the RASLP
group showed complications with two (3%) of these patients
experiencing grade 4 and grade 5 postoperative complica-
tions such as pulmonary thrombosis and fulminant hepati-
tis. CLA procedures are superior to RASLP procedures with
respect to intra- and postoperative complication rates.
However, despite being an evolution of the standard
laparoscopic surgery, LESS recently defied the most basic
tenets of laparoscopy including triangulation of working in-
struments and external spacing to decrease intra- and
extracorporeal clashing,16 and several multichannel plat-
forms have been developed for LESS in urological surgery.17
The development of articulating and bent instrumentation
permits triangulation intracorporeally despite the close
proximity of several instruments via a single port. Cindolo
et al18 reported the first case of LESS transperitoneal adre-
nalectomy using such purpose-built instruments such as the
Triport (Olympus, Tokyo, Japan) and articulated in-
struments. In their procedures, the Triport was inserted
through a 3-cm subcostal incision with carbon dioxide
insufflation of the abdomen. By comparison, our RASLP
procedures involved a rectoscope tube (4 cm in diameter)
being inserted through a 4.5-cm skin incision without carbon
84 D. Hirano et al.dioxide insufflation, resulting in a slightly longer incision.
The operative time and blood loss in the reported LESS
adrenalectomy were 240 minutes and 20 mL, respectively.
The operative time was similar in our RASLP patients; how-
ever, they experienced less blood loss. This could be attrib-
uted to the use of carbon dioxide insufflation during their
operation. Jeong et al19 reported the first study comparing
LESS adrenalectomy and CLA in the treatment of benign
adrenal adenomas, and their results showed no significant
differences in mean operative time, blood loss, and post-
operative hospital stay between the LESS and CLA groups.
The authors concluded that LESS adrenalectomy for benign
adrenal adenoma is comparable to the conventional lapa-
roscopic approach in terms of perioperative parameters, but
withmore desirable cosmetic outcomes. However, in LESS no
proven or documented benefits except for cosmetic advan-
tage exist over the conventional approach, and only expe-
rienced laparoscopic surgeons should attempt this technique
in clinical settings according to the European Association of
Urology guidelines on robotic and single-site surgery in
urology.20 We did not use the same contemporary devices for
LESS surgery when performing RASLP. Even with the use of
developed contemporary instruments, RASLP is likely to be
inferior to LESS surgery because the working space is smaller
in the RASLP as carbon dioxide insufflation is not used.
In conclusion, although this study was based on retro-
spective analysis with different eras and indications for
patients treated with RASLP versus CLA, the perioperative
outcomes measured in the RASLP group were inferior to
those in the CLA group. CLA has so far become our
preferred procedure for patients with adrenal tumor.
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